Pfizer (Italy)

548 papers and 19.2k indexed citations i.

About

In recent decades, authors affiliated with Pfizer (Italy) have published 548 papers, which have received a total of 19.2k indexed citations. Scholars at this organization have produced 279 papers in Pulmonary and Respiratory Medicine, 275 papers in Oncology and 112 papers in Molecular Biology on the topics of Lung Cancer Treatments and Mutations (113 papers), Renal cell carcinoma treatment (75 papers) and Colorectal Cancer Treatments and Studies (66 papers). Their work is cited by papers focused on Pulmonary and Respiratory Medicine (10.3k citations), Oncology (10.2k citations) and Molecular Biology (5.2k citations). Authors at Pfizer (Italy) collaborate with scholars in Italy, United States and France and have published in prestigious journals including New England Journal of Medicine, Journal of Biological Chemistry and Nature Medicine. Some of Pfizer (Italy)'s most productive authors include Benjamin Solomon, Enriqueta Felip, Tiziana Usari, Richard S. Finn, Keith D. Wilner, Dennis J. Slamon, Shrividya Iyer, Camilla Fowst, Yi−Long Wu and Tony Mok.

In The Last Decade

Fields of papers published by authors at Pfizer (Italy)

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers affiliated with Pfizer (Italy) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Pfizer (Italy) at the time of their publication.

Countries citing scholars working at Pfizer (Italy)

Since Specialization
Citations

This map shows the geographic impact of research produced by authors working at Pfizer (Italy). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Pfizer (Italy) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pfizer (Italy) more than expected).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar’s output or impact.

Explore institutions with similar magnitude of impact

Rankless by CCL
2025